PTC Stock Recent News

BOSTON , March 13, 2025 /PRNewswire/ -- PTC (NASDAQ: PTC) today announced that it has appointed Trac Pham to its Board of Directors, effective March 17, 2025. Pham is the former Chief Financial Officer of Synopsys, a recognized leader in electronic design automation and semiconductor development.

PTC Therapeutics is poised for a potential turnaround with key FDA reviews in 2025 for vatiquinone and sepiapterin, despite past revenue declines. The company maintains a strong cash position of over $2 billion, providing a buffer as it awaits regulatory approvals to boost revenue. PTC's diversified pipeline, including vatiquinone for Friedreich's ataxia, could significantly enhance revenue if approved, targeting a $2.8 billion market.

PTC Inc. (PTC) reported earnings 30 days ago. What's next for the stock?

Sometimes, the headline numbers don't tell the whole story. That's definitely the case with industrial software company PTC (PTC 0.05%) and workflow technology company Trimble (TRMB 1.11%).

BOSTON , Feb. 27, 2025 /PRNewswire/ -- PTC (Nasdaq: PTC) today announced that it will participate in the following conferences. What:     Morgan Stanley Technology, Media & Telecom Conference When:    Tuesday, March 4 th, 2025 at 2:35pm PST  What:     Stifel's Inaugural NYC Technology 1:1 Conference When:    Tuesday, March 11 th, 2025 What:      BofA Securities 32nd Annual Industrials, Transportation & Airlines Key Leaders Conference When:     Thursday, May 15 th, 2025 What:      Baird Global Consumer, Technology & Services Conference When:     Tuesday, June 3rd, 2025 What:      Mizuho Technology Conference When:     Tuesday, June 10th, 2025 To view the webcast and replay for conferences please use the link below.Webcast:  https://investor.ptc.com/events-and-presentations/events-calendar/default.aspx   Please note that statements made at each conference are as of the date of the respective conference and PTC does not assume any obligation to update any stat

– Full year 2024 revenue of $807 million, exceeding guidance – – All 2024 clinical and regulatory milestones were achieved on schedule, including four NDA submissions, all of which were accepted for filing – – License and collaboration agreement with Novartis for PTC518 Huntington's disease program closed in January 2025 – – Cash of over $2.0 billion as of January 2025 – WARREN, N.J. , Feb. 27, 2025 /PRNewswire/ -- PTC Therapeutics, Inc., (NASDAQ: PTCT) today announced a corporate update and financial results for the fourth quarter ending December 31, 2024.

WARREN, N.J. , Feb. 20, 2025 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that its executives will participate in fireside chats at the following investor conferences: TD Cowen 45th Annual Health Care 2025 Conference   Tuesday, March 4 at 11:10 a.m.

- PDUFA target action date of Aug. 19, 2025 - WARREN, N.J. , Feb. 19, 2025 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) announced today that the U.S. Food and Drug Administration (FDA) has accepted for filing the New Drug Application (NDA) for vatiquinone for the treatment of children and adults living with Friedreich's ataxia (FA).

The prospect of several more weeks of winter after Punxsutawney Phil saw his shadow may have your mind fretful about more frosty weather, but that shouldn't distract you from the S&P 500's red-hot performance, which has resulted in the index soaring more than 20%.

None of these three stocks are conventionally cheap, but they all have huge growth potential from megatrends already in place, making them attractive stocks for investors to buy for the long term. Here's why electronic design automation (EDA) company Synopsys (SNPS 3.65%), design and product management software company PTC (PTC 0.82%), and advanced composite materials company Hexcel (HXL -1.09%) are stocks worth taking long-term positions on.